PHARMICELL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,560 KRW | -0.54% |
|
-2.80% | -8.40% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2012 | 11.11B 8.22M 11.19M | Sales 2013 | 33.41B 24.72M 33.64M | Capitalization | 164B 121M 165M |
|---|---|---|---|---|---|
| Net income 2012 | -17.64B -13.06M -17.77M | Net income 2013 | -25.7B -19.02M -25.88M | EV / Sales 2012 | 19.8 x |
| Net Debt 2012 | 6.08B 4.5M 6.12M | Net Debt 2013 | 6.33B 4.68M 6.37M | EV / Sales 2013 | 5.1 x |
| P/E ratio 2012 |
-10.9
x | P/E ratio 2013 |
-6.22
x | Employees | - |
| Yield 2012 * |
-
| Yield 2013 |
-
| Free-Float | 90.26% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.54% | ||
| 1 week | -2.80% | ||
| Current month | -5.60% | ||
| 1 month | +0.18% | ||
| 3 months | -1.59% | ||
| 6 months | -16.77% | ||
| Current year | -8.40% |
1 week
5 530.00
5 750.00
1 month
5 500.005 970.00
Current year
5 310.007 320.00
1 year
5 290.009 420.00
3 years
5 290.0020 200.00
5 years
5 290.0026 150.00
10 years
2 790.0026 350.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hyun-Soo Kim
CEO | Chief Executive Officer | 60 | 09-08-18 |
Kwang-Rae Kim
SAM | Sales & Marketing | 54 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Byung-Moo Yoo
BRD | Director/Board Member | 60 | 11-08-11 |
Hyun-Soo Kim
CEO | Chief Executive Officer | 60 | 09-08-18 |
Sung-Nyun Kim
BRD | Director/Board Member | 56 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 112 M€ | +5.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 5,560 | -0.54% | 114,849 |
| 24-05-16 | 5,590 | -1.06% | 209,749 |
| 24-05-14 | 5,650 | +0.36% | 98,606 |
| 24-05-13 | 5,630 | -1.57% | 191,474 |
| 24-05-10 | 5,720 | +1.06% | 157,405 |
End-of-day quote Korea S.E., May 16, 2024
More quotes
Pharmicell Co., Ltd. is a Korea-based company principally engaged in the biopharmaceutical business. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. It also provides steam cell storage services, and mesenchymal stem cells (MSCs) used for research areas and others. In addition, the Company engages in the fashion business, which provides womenâs and menâs apparels under the brand names of Religion and Day. On March 31, 2013, the Company merged with its wholly owned subsidiary, mainly engaged in the manufacture and sale of medicines.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.40% | 247M | |
| -2.32% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| -19.56% | 14.73B | |
| -9.06% | 12.82B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B | |
| -6.32% | 8.35B |
- Stock Market
- Equities
- A005690 Stock
